Plain-English translation of NCT06356662 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Parkinson Disease research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether a medication called can help improve movement symptoms in people with early-stage Parkinson's disease. Researchers will compare how people who take the medication do over time compared to those who receive a placebo (a pill with no active medicine). The goal is to understand both whether the treatment works and whether it is safe.
Parkinson's disease affects movement and can be very challenging to live with. Current treatments don't work for everyone or stop working over time, so researchers are exploring whether this medication might offer a new option to help improve movement symptoms in the early stages of the disease.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to either take the study medication or a placebo over a period of time. Researchers will track how your movement symptoms change and watch for any side effects at different time points during the study. You'll likely have regular clinic visits to assess your symptoms and overall health.
AI-generated summary from trial data · Jul 4, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Enrollment target
~60 participants
Started
January 2024
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in February 2025.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.